BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

427 related articles for article (PubMed ID: 12630015)

  • 1. Alanine aminotransferase (ALT) levels in a normal population and interferon therapy in chronic hepatitis C patients with normal ALT.
    Sakugawa H; Nakasone H; Nakayoshi T; Kawakami Y; Yamashiro T; Maeshiro T; Kinjo F; Saito A; Yakabi S
    Hepatogastroenterology; 2003; 50(49):165-9. PubMed ID: 12630015
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Decreased risk of hepatocellular carcinoma in patients with chronic hepatitis C whose serum alanine aminotransferase levels became less than twice the upper limit of normal following interferon therapy.
    Moriyama M; Matsumura H; Aoki H; Shimizu T; Yamagami H; Shioda A; Kaneko M; Goto I; Tanaka N; Arakawa Y
    Liver Int; 2005 Feb; 25(1):85-90. PubMed ID: 15698403
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Amantadine-HCL in the treatment of chronic hepatitis C in non-responders to alpha-interferon. Effect on ALT serum levels and viral load].
    Parolin MB; Lacerda MA; Lopes RW
    Arq Gastroenterol; 1999; 36(2):63-7. PubMed ID: 10511883
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A 24-week course of high-dose interferon-alpha plus ribavirin for Taiwanese chronic hepatitis C patients with persistently normal or near-normal alanine aminotransferase levels.
    Yu ML; Dai CY; Lee LP; Hou NJ; Hsieh MY; Huang JF; Lin ZY; Chen SC; Hsieh MY; Wang LY; Chang WY; Chuang WL
    Liver Int; 2006 Dec; 26(10):1187-95. PubMed ID: 17105583
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chronic hepatitis C virus infection in renal transplant: treatment and outcome.
    Sharma RK; Bansal SB; Gupta A; Gulati S; Kumar A; Prasad N
    Clin Transplant; 2006; 20(6):677-83. PubMed ID: 17100715
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Is interferon-alpha therapy safe and effective for patients with chronic hepatitis C and inflammatory bowel disease? A case-control study.
    Bargiggia S; Thorburn D; Anderloni A; Ardizzone S; Giorgi A; Bianchi Porro G; Parente F
    Aliment Pharmacol Ther; 2005 Aug; 22(3):209-15. PubMed ID: 16091058
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical features of hepatocellular carcinoma that occur after sustained virological response to interferon for chronic hepatitis C.
    Ikeda M; Fujiyama S; Tanaka M; Sata M; Ide T; Yatsuhashi H; Watanabe H
    J Gastroenterol Hepatol; 2006 Jan; 21(1 Pt 1):122-8. PubMed ID: 16706823
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Interferon monotherapy for patients with chronic hepatitis C and normal serum aminotransferase levels at commencement of treatment.
    Mamori S; Suzuki F; Hosaka T; Akuta N; Someya T; Kobayashi M; Tsubota A; Suzuki Y; Saitoh S; Arase Y; Ikeda K; Kumada H
    J Gastroenterol; 2004 Aug; 39(8):776-82. PubMed ID: 15338372
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chronic infection with hepatitis C virus in patients with elevated or persistently normal serum alanine aminotransferase levels: comparison of hepatic histology and response to interferon therapy.
    Shiffman ML; Stewart CA; Hofmann CM; Contos MJ; Luketic VA; Sterling RK; Sanyal AJ
    J Infect Dis; 2000 Dec; 182(6):1595-601. PubMed ID: 11069229
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of interferon retreatment after relapse for chronic hepatitis C patients with biochemical response after first interferon therapy.
    Arase Y; Ikeda K; Tsubota A; Suzuki Y; Saitoh S; Kobayashi M; Suzuki F; Akuta N; Someya T; Hosaka T; Kobayashi M; Kumada H
    J Gastroenterol; 2004; 39(5):455-60. PubMed ID: 15175944
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interferon sensitivity-determining region of nonstructural region 5A of hepatitis C virus genotype 1b correlates with serum alanine aminotransferase levels in chronic infection.
    Yoshioka K; Ito H; Watanabe K; Yano M; Ishigami M; Mizutani T; Sasaki Y; Goto H
    J Viral Hepat; 2005 Mar; 12(2):139-45. PubMed ID: 15720528
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Risk factors for the development of hepatocellular carcinoma among patients with chronic hepatitis C who achieved a sustained virological response to interferon therapy.
    Tokita H; Fukui H; Tanaka A; Kamitsukasa H; Yagura M; Harada H; Okamoto H
    J Gastroenterol Hepatol; 2005 May; 20(5):752-8. PubMed ID: 15853990
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interferon therapy in hemodialysis patients with chronic hepatitis C virus infection induces a high rate of long-term sustained virological and biochemical response.
    Espinosa M; Rodriguez M; Martin-Malo A; Alvarez de Lara MA; Gonzalez R; Lopez-Rubio F; de la Mata M; Aljama P
    Clin Nephrol; 2001 Mar; 55(3):220-6. PubMed ID: 11316242
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Liver biopsy findings for HIV-infected patients with chronic hepatitis C and persistently normal levels of alanine aminotransferase.
    Sánchez-Conde M; Berenguer J; Miralles P; Alvarez F; Carlos Lopez J; Cosin J; Pilar C; Ramirez M; Gutierrez I; Alvarez E
    Clin Infect Dis; 2006 Sep; 43(5):640-4. PubMed ID: 16886160
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of long-term interferon therapy for refractory chronic hepatitis c: preventive effect on hepatocarcinogenesis.
    Saito Y; Saito H; Tada S; Nakamoto N; Horikawa H; Kurita S; Kitamura K; Ebinuma H; Ishii H; Hibi T
    Hepatogastroenterology; 2005; 52(65):1491-6. PubMed ID: 16201104
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chronic hepatitis C in patients with persistently normal alanine transaminase levels.
    Shiffman ML; Diago M; Tran A; Pockros P; Reindollar R; Prati D; Rodríguez-Torres M; Lardelli P; Blotner S; Zeuzem S
    Clin Gastroenterol Hepatol; 2006 May; 4(5):645-52. PubMed ID: 16630770
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of iron depletion on long-term response to interferon-alpha in patients with chronic hepatitis C who previously did not respond to interferon therapy.
    Tsai NC; Zuckerman E; Han SH; Goad K; Redeker AG; Fong TL
    Am J Gastroenterol; 1997 Oct; 92(10):1831-4. PubMed ID: 9382046
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reduction therapy of alanine aminotransferase levels prevent HCC development in patients with HCV-associated cirrhosis.
    Rino Y; Tarao K; Morinaga S; Ohkawa S; Miyakawa K; Hirokawa S; Masaki T; Tarao N; Yukawa N; Saeki H; Takanashi Y; Imada T
    Anticancer Res; 2006; 26(3B):2221-6. PubMed ID: 16821591
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Therapy of hepatitis C: patients with normal aminotransferase levels.
    Marcellin P; Lévy S; Erlinger S
    Hepatology; 1997 Sep; 26(3 Suppl 1):133S-136S. PubMed ID: 9305678
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and tolerance of interferon-alpha in the treatment of chronic hepatitis C in end-stage renal disease patients on hemodialysis.
    Rocha CM; Perez RM; Ferreira AP; Carvalho-Filho RJ; Pace FH; Silva IS; Pestana JO; Lanzoni VP; Silva AE; Ferraz ML
    Liver Int; 2006 Apr; 26(3):305-10. PubMed ID: 16584392
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.